Copyright © Inderes 2011 - present. All rights reserved.

Medicover

227,00 SEK

-1,73 %

Mindre end 1K følgere

MCOV B

NASDAQ Stockholm

Health Care Providers

Health Care

-1,73 %
-6,78 %
-15,30 %
-5,22 %
+18,23 %
+24,73 %
+64,02 %
+63,07 %
+246,56 %

Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.

Læs mere
Markedsværdi
34,85 mia. SEK
Aktieomsætning
10,53 mio. SEK
Omsætning
23,99 mia.
EBIT %
3,36 %
P/E
176,71
Udbytteafkast, %
0,76 %
Omsætning og EBIT-margin

Omsætning mia.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
10.2
2026

Årsrapport '25

29.4
2026

Generalforsamling '26

29.4
2026

Delårsrapport Q1'26

ViserAlle indholdstyper
Eksterne analyser

Medicover: Execution remains solid - ABG

* Operational leverage supports beat on adj. EBITDA* Adj. EBITDA revised by +1-0% for '25e-'27e* Unchanged outlook and fair value range of SEK 220-300Continues to show strengthQ3 proved marginally weaker than expected on sales, but operational leverage...

Medicover

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

Medicover: Margins expand, despite slower growth - ABG

* +5%/+3% adj. EBITDA vs ABGSCe/Infront cons in Q3* Cons estimates likely up 1-2% on adj. EBITDA '25e* Somewhat lower sales but profitability continues to improveQ3 resultsMedicover reported a solid Q3 with a miss on sales but a beat on adj. EBITDA (...

Medicover
Eksterne analyser

Medicover: Strong and stable core, minor adjustments - ABG

* Q3'25 numbers due on 5 November at 07:45 CET* Adj. EBITDA down 1% for '25e-'27e* Fair value range unchanged at SEK 220-300 Q3'25 expectations For Q3, we expect Medicover to continue to deliver strong growth in its core regions and drive margin expansion...

Medicover
Eksterne analyser

Medicover: A charmingly aggressive CEO - ABG

* Scale and presence underpin growth and margin expansion* Sharper execution on cross-segment synergies* Trading at ~13x '25e EV/EBITDAPresence mattersWe hosted Medicover’s CEO John Stubbington and CFO Anand Patel for lunch earlier today. The discussion...

Medicover
Eksterne analyser

Medicover: Still shining bright - ABG

Q2 results Medicover reported an adj. EBITDA beat in Q2 (+7%/+7% vs. ABGSCe/cons), with better than expected margins in both segments. Q2 sales was EUR 597m (0% vs ABGSCe, 0% vs cons). Total organic sales growth in Q2 was +14% (ABGSCe +16%).Adj. EBITDA...

Medicover
Eksterne analyser

Medicover: Full steam ahead - ABG

Q2'25 numbers due on 24 July at 07:45 CET Adj. EBITDA flat, EBIT up 2% for '25e-'27e Unchanged story, fair value range up to SEK 190-270 (180-260) Q2'25 expectations Ahead of Q2, Medicover’s strong growth trajectory and expanding margins are expected...

Medicover
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.